methsuximide

Methsuximide is an oral anticonvulsant medication in the succinimide class, primarily used to control absence (petit mal) seizures in patients with epilepsy who have not responded to other treatments. It works by suppressing abnormal electrical activity in the brain, specifically reducing paroxysmal spike-and-wave patterns associated with lapses of consciousness during absence seizures. The drug acts by depressing the motor cortex and raising the threshold for convulsive stimuli within the central nervous system[1][2][6][7]. Methsuximide is available as a 300 mg capsule and is marketed under brand names such as Celontin[5][8]. It was developed and is manufactured by Pfizer[7].

Brand names

Celontin

Other names

Petinutinmesuximide